COVID-19: US Eli Lilly, Corona antibody drug: Hospitalization rate decreased in clinical trials
US Pharmaceutical Eli Lilly:
On September 16, Eli Lilly announced the results of a mid-term clinical trial of a new coronavirus antibody drug under development.
Administration of antibody drug:
The administration of antibody drugs reduced the hospitalization rate for patients with mild to moderate new corona.
Eli Lilly also started a late-stage clinical trial in August.
Mid-term clinical trials:
The mid-term clinical trial was conducted on approximately 450 new corona patients.
Different doses of antibody drug were administered.
Results of clinical trial:
As a result, the hospitalization rate of patients who received antibody drugs was lower than that of patients who received placebo (placebo) as a whole.
In addition, the viral load of patients who received medium-dose antibody drugs was significantly lower than that of low-dose and high-dose administration.
Mid-term clinical trials are ongoing and are scheduled to be completed in the October-December period.
Antibody drug “LY-CoV555”
Lily’s monoclonal antibody drug “LY-CoV555” was jointly developed with Abcelera Biologics of Canada.
Antibodies extracted from recovery patients of the new corona are models.
By preventing the new coronavirus from invading human cells,
It is expected to be effective in preventing infection and aggravation.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXMZO63947180X10C20A9000000/
Lilly’s LY-CoV555 Shows Promise Targeting COVID-19 With Phase 2 Interim Analysis
Eli Lilly and Company (NYSE: LLY)
announced that proof of concept data from an interim analysis of the BLAZE-1 clinical trial reveals a reduced rate of hospitalization for patients treated with LY-CoV555.
LY-CoV555
An ongoing randomized,
double-blind,
placebo-controlled Phase 2 studyreveals centers on the investigational product known as LY-CoV555.
AbCellera
Developed thanks to a partnership
affording access to powerful drug discovery technology from AbCellera,in combination with dedicated Lilly scientists working day and night starting back in the early Spring,
this potent monoclonal antibody demonstrates real promise as a regimen targeting both COVID-19 prevention and treatment.
Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19
TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization
was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program.
also selected by Eli Lilly
Now, local media (WSYX/WTTE)
reports that the Columbus-based site was also selected by Eli Lilly for participation in the BLAZE-1 study investigating advanced monoclonal antibodies targeting COVID-19.LY-CoV555 and LY-CoV016,
This particular study involves LY-CoV555 and LY-CoV016, one of which originated out of a collaboration between Lilly and AbCellera (March) and the other a license deal with Junshi Biosciences in China (May).
Dr. Samir Arora
founded Aventiv Research back in 2007; the Columbus principal investigator recently expressed his excitement about this antibody treatment under investigationemphasizing to local Columbus media that if this particular treatment proves successful in clinical trials, it would be one of the first medications on the market to help patients fight off COVID-19.